Blood Culture Tests Market Report 2025

This Blood Culture Tests market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The blood culture tests market size has grown rapidly in recent years. It will grow from $6.79 billion in 2024 to $7.57 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to increase in prevalence of infectious diseases, aging population, advances in healthcare infrastructure, rise in research and development.

The blood culture tests market size is expected to see rapid growth in the next few years. It will grow to $13.09 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to rising hospital-acquired infections, growing demand for point-of-care (poc) testing, increased healthcare spending, regulatory approvals. Major trends in the forecast period include telemedicine and remote testing, automation and ai, multiplex testing, sepsis management, infectious disease surveillance.

The rising incidence of infectious diseases is expected to drive the growth of the blood culture test market. Infectious diseases are caused by pathogens such as viruses, bacteria, fungi, and parasites. These harmful microorganisms can enter the body from external sources or through contact with an infected individual. Diseases like COVID-19, tuberculosis, the flu, measles, HIV, and strep throat can cause temporary discomfort, severe tissue damage, or even death. The World Health Organization identifies infectious diseases as the second leading cause of death globally. This increase in infectious disease cases has fueled the demand for blood culture tests, which help determine whether a patient has bacteremia or septicemia, potentially life-threatening conditions. For example, in August 2024, according to a report by the UK Health Security Agency, as of December 31, 2022, there were 3,732 confirmed mpox cases in the UK, primarily in England. By May 31, 2023, 21 additional cases were reported, mainly in England, with one in Scotland. As a result, the growing incidence of infectious diseases is driving demand for blood culture tests.

The rise in antibiotic resistance is expected to drive the growth of the blood culture test market in the future. Antibiotic resistance refers to the ability of bacteria, viruses, or other microorganisms to resist the effects of antibiotics or antimicrobial drugs that were previously effective in treating infections caused by these organisms. The increase in antibiotic-resistant infections requires more comprehensive diagnostic testing, including blood culture tests, to identify the most effective treatment options. For example, in November 2023, according to a report from the World Health Organization, a US-based intergovernmental organization, antibiotic-resistant infections are projected to increase from $1 trillion in 2030 to between $1 trillion and $3.4 trillion by 2050. Thus, the rising demand due to increasing antibiotic resistance is contributing to the growth of the blood culture test market.

Technological innovation emerges as a prominent trend influencing the blood culture test market. In the dynamic landscape of pharmaceuticals, biologics, nutraceuticals, and medical devices, innovation is key to meeting evolving industry requirements. The imperative to bring new products to market efficiently and cost-effectively has led manufacturers to develop cutting-edge blood culture testing technologies. Notably, Labcorp introduced the Labcorp OnDemandTM at-home collection kit in May 2022. This innovative kit utilizes dried blood technology to measure hemoglobin A1c from a small blood sample, providing users with insights into their average blood sugar levels over time. Technological advancements like this not only enhance accuracy and safety but also enable individuals to monitor their health conveniently from the comfort of their homes, fostering the growth of the blood culture test market.

Major companies in the organic blood culture tests market are focusing on developing advanced technologies, such as clinical chemistry technologies, to improve diagnostic accuracy, decrease turnaround times, and enhance patient management through integrated testing solutions that deliver comprehensive insights into infections and related health issues. Clinical chemistry technologies refer to diagnostic methods and instruments utilized to analyze bodily fluids, primarily blood, to measure chemical components and evaluate health conditions. For example, in April 2024, Mindray Medical International Limited, a medical device company based in China, launched mid-volume laboratories. These innovations demonstrate Mindray's dedication to supporting mid-volume laboratories by offering simple yet effective solutions that boost diagnostic capabilities while meeting the growing demands of healthcare providers.

In April 2022, BioMérieux India Pvt Ltd, a provider of in vitro diagnostic solutions based in India, acquired Specific Diagnostics for an undisclosed amount. This acquisition aims to improve public health by delivering innovative in vitro diagnostic solutions. Specific Diagnostics is an India-based company that produces the SPECIFIC REVEAL Rapid AST system for testing.

Major companies operating in the blood culture tests market include Becton, Dickinson and Company, BioMerieux SA, Thermo Fisher Scientific Inc., Luminex Corporation, Danaher Corporation, Terumo Corporation, Bruker Corporation, F. Hoffmann-La Roche AG, Biobase Biotech Co. Ltd., Scenker Biological Technology Co. Ltd., Bulldog Bio, Anaerobe Systems Inc., Himedia Laboratories Pvt. Ltd., Autobio Diagnostics Co. Ltd., Axiom Laboratories, Biosystems Inc., BINDER GmBH, Roche Diagnostics, Mikroscan Technologies Inc., Labotronics Ltd., Hardy Diagnostics, OpGen Inc., Meditech Technologies India Private Limited, Siemens Healthineers, Abbott Laboratories, Cepheid, T2 Biosystems Inc., Beckman Coulter Inc., Accelerate Diagnostics, Bio-Rad Laboratories Inc., Hologic Inc., Quidel Corporation, Copan Diagnostics Inc., Greiner Bio-One International GmbH, Carl Zeiss AG, Nanosphere Health Sciences, GenMark Diagnostics, Meridian Bioscience Inc., Nikon Corporation.

Blood culture tests are diagnostic procedures designed to identify disease-causing microorganisms present in the bloodstream. These tests play a crucial role in detecting infections caused by various microorganisms such as bacteria, yeast, and other foreign invaders in a blood sample.

The primary methods employed in blood culture tests include conventional/manual methods and automated methods. The conventional or manual method is utilized to detect invaders like bacteria, yeast, and other microorganisms in a blood specimen. Manual testing involves the hands-on examination and interpretation of results by skilled testers. Blood culture products encompass consumables, instruments, and software and services that leverage technologies such as culture-based technology, molecular technologies, microarrays, PCR (polymerase chain reaction), PNA-FISH (peptide nucleic acid - fluorescent in situ hybridization), and proteomics technology. These technologies are applied in the detection of bacteremia, fungemia, and mycobacterial infections. Blood culture tests are commonly utilized by hospital laboratories, reference laboratories, academic research laboratories, and other testing facilities.

The blood culture tests market research report is one of a series of new reports that provides blood culture tests market statistics, including blood culture tests industry global market size, regional shares, competitors with a blood culture tests market share, detailed blood culture tests market segments, market trends and opportunities, and any further data you may need to thrive in the blood culture tests industry. This blood culture tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the blood culture tests market in 2024. The regions covered in the blood culture tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the blood culture tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The blood culture tests include revenues earned by entities by micro sampling technology and blood chemistry analyzer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.